Topical anti-inflammatory activity of human recombinant epidermal growth factor.
The topical anti-inflammatory activity of epidermal growth factor (EGF) was evaluated in inflammation models induced by 12-Otetradecanoylphorbol-13-acetate, croton oil and arachidonic acid. When EGF (1.5, 3 or 6 microg/ear) was coapplied with each inflammatory agent, there was a dose-related decrease in inflammation as assessed by ear punch weights, myeloperoxidase activity as well as by histopathological studies. The precise anti-inflammatory action of EGF is yet unclear, but we believe that interference with arachidonic acid metabolism may play an important role.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004431:Ear, External / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced* / Q000473:pathology; D051379:Mice; D008954:Models, Biological; D009195:Peroxidase / Q000187:drug effects / Q000378:metabolism*; D011565:Psoriasis / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology